What are alternative medications to Roclatan (netarsudil/latanoprost) for lowering intraocular pressure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Roclatan Alternatives for Lowering Intraocular Pressure

For patients requiring alternatives to Roclatan (netarsudil/latanoprost), prostaglandin analogs remain first-line therapy, with bimatoprost offering the greatest IOP reduction (31-33% at peak, 28-29% at trough), though latanoprost provides the best tolerability profile and should be preferred for most patients. 1, 2

First-Line Monotherapy Options

Prostaglandin Analogs (Preferred Class)

The prostaglandin analogs are the most efficacious and well-tolerated glaucoma medications, requiring only once-daily dosing 2:

  • Bimatoprost 0.03%: Achieves the highest IOP reduction (31-33% at peak, 28-29% at trough) but carries increased risk of conjunctival hyperemia compared to latanoprost (OR 3.3,95% CI 2.5-4.5) 1, 3, 4

  • Latanoprost 0.005%: Provides excellent IOP reduction (31% at peak, 28% at trough) with the most favorable tolerability profile among prostaglandins. This makes it the optimal first choice for most patients 1, 3

  • Travoprost 0.004%: Similar efficacy to latanoprost (31% at peak, 29% at trough) with intermediate hyperemia risk 1, 3

  • Tafluprost 0.0015%: Preservative-free option with balanced efficacy and tolerability, suitable for patients with ocular surface disease 3

Clinical Pearl: While bimatoprost achieves slightly greater IOP reduction (approximately 1-2 mmHg more than latanoprost), this difference may not be clinically meaningful for most patients, and the increased hyperemia risk often makes latanoprost the better practical choice 1, 5.

Beta-Blockers (Alternative First-Line)

  • Timolol 0.5%: Reduces IOP by 27% at peak and 26% at trough. Well-established efficacy but requires twice-daily dosing 1, 4

Critical Contraindications: Avoid in patients with asthma, COPD, bradycardia, or heart block. Nighttime dosing should be avoided as it may contribute to visual field progression via nocturnal hypotension 2

  • Betaxolol 0.5%: Cardioselective beta-blocker with 23% peak and 20% trough IOP reduction. Minimizes but doesn't eliminate pulmonary risks 1, 2

Second-Line Monotherapy Options

Alpha-2 Adrenergic Agonists

  • Brimonidine 0.2%: Reduces IOP by 25% at peak and 18% at trough. Less effective than prostaglandins (approximately 2 mmHg less reduction than latanoprost) but may have neuroprotective properties 1, 6

Major Limitation: High rate of ocular allergy (significantly more than latanoprost, p<0.001) and systemic side effects including fatigue and dry mouth 6

Carbonic Anhydrase Inhibitors

  • Dorzolamide 2.0%: Achieves 22% peak and 17% trough IOP reduction 1, 4
  • Brinzolamide 1.0%: Similar efficacy (17% at both peak and trough) 1, 4

Both require 2-3 times daily dosing and are contraindicated in sulfonamide allergy 2

Rho Kinase Inhibitors

  • Netarsudil 0.02%: Reduces IOP by 10-20% but ranks lower in efficacy compared to prostaglandins. However, it has a relatively favorable safety profile with lower hyperemia incidence than some prostaglandins 2, 7

Common Side Effects: Conjunctival hyperemia (18%), corneal verticillata (15%), instillation site pain (20%) 2, 8

Combination Therapy Options

When monotherapy is insufficient:

Fixed-Dose Combinations (Most Convenient)

  • Latanoprost/Timolol: Demonstrates superior IOP lowering compared to individual components, making it an excellent step-up option 1

  • Latanoprostene bunod 0.024%: Nitric oxide-donating prostaglandin analog with dual mechanism (trabecular and uveoscleral outflow enhancement). May offer additional benefits for ocular blood flow and retinal ganglion cell survival 9

Switching Strategy: When switching from latanoprost monotherapy or latanoprost plus 1-2 additional agents to netarsudil/latanoprost FDC, patients achieved mean IOP reductions of 18.5-21.2% with simplified once-daily dosing 10

Practical Treatment Algorithm

  1. Start with latanoprost 0.005% once daily (evening dosing) for optimal efficacy-tolerability balance
  2. If inadequate response: Switch to bimatoprost 0.03% for maximum IOP reduction (accept higher hyperemia risk)
  3. If prostaglandin intolerant: Use timolol 0.5% twice daily (if no cardiac/pulmonary contraindications)
  4. If monotherapy insufficient: Add fixed-combination latanoprost/timolol or consider latanoprostene bunod
  5. For patients requiring netarsudil component: Netarsudil/latanoprost FDC provides additional 15-21% IOP reduction when switching from latanoprost-based regimens 10

Critical Caveats

  • Prostaglandin washout: IOP-lowering effects dissipate within 4 weeks of discontinuation, making this an appropriate washout period 1
  • Iris pigmentation: All prostaglandins cause permanent iris darkening and reversible eyelash changes 2
  • Target IOP: Aim for at least 20% reduction from baseline, though higher baseline pressures may require greater reductions 2
  • Cost considerations: Generic latanoprost and timolol offer cost-effective alternatives to newer branded medications while maintaining excellent efficacy 1

References

Related Questions

Can a patient be treated concurrently with latanoprost and Rhopressa (netarsudil)?
What is the mechanism of action of latanoprostene bunod?
What is the recommended dosage and treatment plan for Vyzulta (latanoprostene bunod) in patients with glaucoma?
In a patient admitted with an acute illness, should linagliptin be continued, and what criteria (e.g., ability to eat, hemodynamic stability, renal function) determine whether to hold or resume the medication?
Is hematuria in this patient an indication to review apixaban 5 mg twice daily?
When can a patient with a history of inadequately treated latent tuberculosis, no symptoms, normal chest X‑ray, who has been on rifampin 600 mg daily for three days and has completed three sputum collections on a detox unit, be transferred to a residential program?
What is the differential diagnosis for a 14-year-old presenting with green‑yellow (biliary) vomiting and right upper quadrant pain?
In a 6‑month‑old infant with a fecal lactoferrin level of 17.3 µg/g, what does this indicate and what diagnostic and management steps are recommended?
Is it feasible to conduct a network meta‑analysis of anastomotic reinforcement techniques (hand‑sewn, stapled, and compression‑ring devices) in elective left‑sided colon cancer resections, and what would be an appropriate title for such a study?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.